Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

Zacks05-03

Kymera Therapeutics, Inc. KYMR reported a loss of 69 cents per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 73 cents. In the year-ago quarter, Kymera ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432900588?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","is_english":true,"pubTime":"2024-05-03 21:57","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2432900588","market":"us","top_or_hot":-1,"title":"Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus","media":"Zacks","content":"<div>\n<p>Kymera Therapeutics, Inc. KYMR reported a loss of 69 cents per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 73 cents. In the year-ago quarter, Kymera ...</p>\n\n<a href=\"https://finance.yahoo.com/news/kymera-kymr-q1-loss-narrower-135700873.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-03 21:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/kymera-kymr-q1-loss-narrower-135700873.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kymera Therapeutics, Inc. KYMR reported a loss of 69 cents per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 73 cents. In the year-ago quarter, Kymera ...</p>\n\n<a href=\"https://finance.yahoo.com/news/kymera-kymr-q1-loss-narrower-135700873.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://finance.yahoo.com/news/kymera-kymr-q1-loss-narrower-135700873.html","article_id":"2432900588","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432900588","pubTimestamp":1714744620,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Kymera Therapeutics, Inc. KYMR reported a loss of 69 cents per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 73 cents. In the year-ago quarter, Kymera reported a loss of 70 cents per share.Collaboration revenues totaled $10.3 million, which missed the Zacks Consensus Estimate of $12 million. Revenues increased 8.7% from the year-ago quarter’s level.Collaboration revenues in the first quarter were attributable to the company’s association with bigwig Sanofi SNY.Shares of KYMR have surged 42.6% year to date against the industry’s decline of 7.6%.As of Mar 31, 2024, Kymera had approximately $745 million in cash, cash equivalents, and investments. The current cash balance is expected to provide a runway into the first half of 2027.Kymera Therapeutics, Inc. price-consensus-eps-surprise-chart | Kymera Therapeutics, Inc. Quote. Another pipeline candidate, KT-294, is a once-daily, oral TYK2 degrader with the potential to deliver biologics-like acti","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","KYMR":"Kymera Therapeutics, Inc.","BK4139":"生物科技","BK4588":"碎股","BK4007":"制药","ANIP":"ANI Pharmaceuticals, Inc.","SNY":"赛诺菲安万特","AMRN":"阿玛琳"},"translate_title":"Kymera(KYMR)Q1损失小于预期，管道成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRN":1,"ANIP":1,"KYMR":1,"SNY":1},"content_text":"Kymera Therapeutics, Inc. KYMR reported a loss of 69 cents per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 73 cents. In the year-ago quarter, Kymera reported a loss of 70 cents per share.\nCollaboration revenues totaled $10.3 million, which missed the Zacks Consensus Estimate of $12 million. Revenues increased 8.7% from the year-ago quarter’s level.\nCollaboration revenues in the first quarter were attributable to the company’s association with bigwig Sanofi SNY.\nShares of KYMR have surged 42.6% year to date against the industry’s decline of 7.6%.\nImage Source: Zacks Investment Research\nQuarter in Detail\nResearch and development expenses amounted to $48.8 million, up 15.6% year over year. This was due to increased expenses related to the investment in the company’s proprietary targeted protein degradation platform and discovery programs, as well as a rise in occupancy and related costs due to continued growth in the research and development organization.\nGeneral and administrative expenses totaled $14.4 million, up 14.4% year over year due to an increase in legal and professional service fees.\nIn January 2024, KYMR announced the closing of its upsized underwritten equity offering, resulting in net proceeds of approximately $301 million.\nAs of Mar 31, 2024, Kymera had approximately $745 million in cash, cash equivalents, and investments. The current cash balance is expected to provide a runway into the first half of 2027.\nManagement expects the cash balance to provide the company with sufficient leeway beyond the phase II data for KT-474, as well as additional proof-of-concept data for KT-253 and KT-333, and several clinical inflection points for its STAT6 and TYK2 programs.\n\nKymera Therapeutics, Inc. Price, Consensus and EPS Surprise \n  \nKymera Therapeutics, Inc. price-consensus-eps-surprise-chart | Kymera Therapeutics, Inc. Quote\n\nKey Pipeline Updates\nEnrollment is underway in the two randomized, placebo-controlled phase II studies evaluating KT-474 for the treatment of hidradenitis suppurativa and atopic dermatitis. These studies are being conducted by Sanofi. Top-line data is expected to be reported in the first half of 2025.\nKymera’s first-in-class oral STAT6 degrader, KT-621, is a once-daily oral STAT6 degrader with the potential to deliver dupilumab-like activity in multiple diseases, including atopic dermatitis, asthma, and chronic obstructive pulmonary disorder, among others. Kymera plans to initiate a phase I study on KT-621 in the second half of 2024 with results expected in the first half of 2025.\nAnother pipeline candidate, KT-294, is a once-daily, oral TYK2 degrader with the potential to deliver biologics-like activity in conditions such as inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus, among others. Kymera expects to initiate an early-stage study on KT-294 in the first half of 2025 with results expected in the second half.\nThe dose escalation portion of the phase Ia study on KT-253 for the treatment of liquid and solid tumors is ongoing.\nZacks Rank and Other Stocks to Consider\nKymera currently carries a Zacks Rank #2 (Buy).\nSome better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. ANIP and Amarin AMRN. While ANIP sports a Zacks Rank #1 (Strong Buy) at present, AMRN carries the same rank as Kymera. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for ANI Pharmaceuticals’ 2024 EPS have improved from $4.25 to $4.44. Shares of ANIP have jumped 21.7% year to date.\nANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 109.06%.\nIn the past 90 days, the 2024 loss per share estimate for Amarin has narrowed by two cents. Shares of the company have risen 5.5% year to date.\nAMRN’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 118.75%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nSanofi (SNY) : Free Stock Analysis Report\nAmarin Corporation PLC (AMRN) : Free Stock Analysis Report\nANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report\nKymera Therapeutics, Inc. (KYMR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432900588"}